CDIO (Cardio Diagnostics Holdings) Total Stockholders Equity: $8.90 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIO Cardio Diagnostics Holdings Inc CDIO
49 GF Score
Price $1.57
GF Value $2.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cardio Diagnostics Holdings Total Stockholders Equity?

Cardio Diagnostics Holdings CDIO +0.40% 49 Total Stockholders Equity is $8.90 Mil as of Mar. 2026. GuruFocus rates CDIO with a GF Score™ of 49/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 3 warning signs investors should review.

Cardio Diagnostics Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $8.90 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cardio Diagnostics Holdings's Book Value per Share for the quarter that ended in Mar. 2026 was $3.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cardio Diagnostics Holdings's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.06.

Cardio Diagnostics Holdings  (NAS:CDIO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cardio Diagnostics Holdings's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(8.903-0)/2.959
=3.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cardio Diagnostics Holdings's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.368 + 0.165) / 8.903
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardio Diagnostics Holdings Total Stockholders Equity Related Terms

Cardio Diagnostics Holdings Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cardio Diagnostics Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardio Diagnostics Holdings Total Stockholders Equity Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 1.07 4.30 2.96 9.56 6.97

Cardio Diagnostics Holdings Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.38 9.73 8.15 6.97 8.90
CDIO
49GF Score
Cardio Diagnostics Holdings Inc CDIO
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $8.90 Mil mean?
Cardio Diagnostics Holdings (CDIO) has a Total Stockholders Equity of $8.90 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cardio Diagnostics Holdings and its competitors.
Is Cardio Diagnostics Holdings' Total Stockholders Equity too high?
Cardio Diagnostics Holdings' current Total Stockholders Equity is $8.90 Mil. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Total Stockholders Equity compare to ERNA and LABT?
Cardio Diagnostics Holdings' Total Stockholders Equity of $8.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cardio Diagnostics Holdings and its competitors. Cardio Diagnostics Holdings's current Total Stockholders Equity is $8.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.2% below its estimated fair value. The current Total Stockholders Equity is $8.90 Mil. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Total Stockholders Equity is $8.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?

Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued. The current stock price of $1.57 is trading 43.2% below its estimated GF Value™ of $2.77. GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.

Key valuation signals for CDIO:

  • Total Stockholders Equity: $8.90 Mil
  • GF Value™: $2.77 vs. price of $1.57 (43.2% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardio Diagnostics Holdings Business Description

Address 311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score

Get the complete analysis for CDIO

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$2.77
GF Value